BIX 2026 to Spotlight the Future of Stem Cell and Global Biopha rma M&A
Monday, August 24, 2026

BIOPLUS-INTERPHEX KOREA 2026 (BIX2026), Korea’s leading bio and pharmaceutical convention, hosted by Korea Biotechnology Industry Organization (KoreaBIO) and organized by RX, has ann ounced this year’s conference keynote speakers and opened registration.
BIX is a business platform that brings together companies, research institu tions, and investors from Korea and abroad to explore collaboration opportunities. BIX 2026 will feature a range of programs, including a specialized conference covering the latest developments in biotechnology, market trends, and investment and business development strategies, as well as exhibition s, partnering programs, and business networking events.
This year’s keynote sessions will focus on the future of research and trea tment for nervous system diseases using stem cells and the current M&A tren ds in the global pharmaceutical and biotech industries, respectively.
Temple, who will deliver the opening-day keynote on October 28, is Co-found er and Scientific Director of the Neural Stem Cell Institute (NSCI) and Co-founder and Chief Scientific Officer (CSO) of Luxa Biotechnology LLC. She i s a world-renowned researcher in the fields of stem cells and neuroscience, having served as President of the International Society for Stem Cell Resea rch (ISSCR) and been elected to the National Academy of Medicine.
In her keynote, “Human Stem Cells: Transforming the Fight Against Nervous System Disease”, she will explore how human stem cell technologies are tra nsforming the way nervous system diseases are studied and treated. The sess ion will cover applications ranging from disease modeling and drug discover y to cell therapy, highlighting the translation of stem cell research into therapeutic development.
On October 29, Stuart Cable, Global Head of Mergers & Acquisitions and Vice Chair at Goodwin, will take the stage as the second keynote speaker. Cable is a biopharmaceutical M&A expert who advises pharmaceutical and biotechnol ogy companies on mergers and acquisitions, corporate governance, and capita l markets. He has participated in numerous global biotech M&A transactions, including Sanofi’s acquisition of Blueprint Medicines, Merck’s acquisition of SpringWorks Therapeutics, and AstraZeneca’s acquisition of Fusion Pha rmaceuticals.
He will examine “Current Trends in Biopharma M&A”, the acquisition of inn ovative biotech companies by big pharma and mid-sized pharmaceutical compan ies. The session will cover key aspects of the current M&A landscape, inclu ding deal flow, deal size and structure, executive compensation, material a dverse effects (MAE), public versus private targets, and regulatory conside rations.
In addition to these two keynote sessions, BIX 2026 will feature a variety of specialized sessions covering technological and market developments in t he bioindustry. Industry leaders from biotech and pharmaceutical companies, research institutions, and investment firms will participate to share the l atest R&D trends, strategies for global market entry, investment, technolog y commercialization, and business development.
Pre-registration for BIX 2026 is open through August 31. Discounts on passe s are available for those who register during the early-bird period. Regist ration and more details are available through the official BIX website.